Abstract

Hyperinsulinemia often precedes type 2 diabetes. Palmitoylation, implicated in exocytosis, is reversed by acyl-protein thioesterase 1 (APT1). APT1 biology was altered in pancreatic islets from humans with type 2 diabetes, and APT1 knockdown in nondiabetic islets caused insulin hypersecretion. APT1 knockout mice had islet autonomous increased glucose-stimulated insulin secretion that was associated with prolonged insulin granule fusion. Using palmitoylation proteomics, we identified Scamp1 as an APT1 substrate that localized to insulin secretory granules. Scamp1 knockdown caused insulin hypersecretion. Expression of a mutated Scamp1 incapable of being palmitoylated in APT1-deficient cells rescued insulin hypersecretion and nutrient-induced apoptosis. High-fat-fed islet-specific APT1-knockout mice and global APT1-deficient db/db mice showed increased β cell failure. These findings suggest that APT1 is regulated in human islets and that APT1 deficiency causes insulin hypersecretion leading to β cell failure, modeling the evolution of some forms of human type 2 diabetes.

Original languageEnglish
Pages (from-to)332-344.e7
JournalCell metabolism
Volume35
Issue number2
DOIs
StatePublished - Feb 7 2023

Keywords

  • S-acylation
  • acyl-protein thioesterases
  • beta cell failure
  • lipotoxicity
  • type 2 diabetes

Fingerprint

Dive into the research topics of 'Palmitoylation couples insulin hypersecretion with β cell failure in diabetes'. Together they form a unique fingerprint.

Cite this